Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.

Although androgen ablation therapy is effective in treating primary prostate cancers, a significant number of patients develop incurable castration-resistant disease. Recent studies have suggested a potential synergy between vaccination and androgen ablation, yet the enhanced T-cell function is transient. Using a defined tumor antigen model, UV-8101-RE, we found that concomitant castration significantly increased the frequency and function of antigen-specific CD8(+) T cells early after the immunization of wild-type mice. However, at a late time point after immunization, effector function was reduced to the same level as noncastrated mice and was accompanied by a concomitant amplification in CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) following immunization. We investigated whether Treg expansion occurred following castration of prostate tumor-bearing mice. In the prostate-specific Pten(-/-) mouse model of prostate cancer, we observed an accelerated Treg expansion in mice bearing the castration-resistant endogenous prostate tumor, which prevented effector responses to UV-8101-RE. Treg depletion together with castration elicited a strong CD8(+) T-cell response to UV-8101-RE in Pten(-/-) mice and rescued effector function in castrated and immunized wild-type mice. In addition, Treg expansion in Pten(-/-) mice was prevented by in vivo interleukin (IL)-2 blockade suggesting that increased IL-2 generated by castration and immunization promotes Treg expansion. Our findings therefore suggest that although effector responses are augmented by castration, the concomitant expansion of Tregs is one mechanism responsible for only transient immune potentiation after androgen ablation.

[1]  C. Miao,et al.  In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  H. Hackstein,et al.  Testosterone Replacement Effectively Inhibits the Development of Experimental Autoimmune Orchitis in Rats: Evidence for a Direct Role of Testosterone on Regulatory T Cell Expansion , 2011, The Journal of Immunology.

[3]  G. Hill,et al.  CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis , 2011, Proceedings of the National Academy of Sciences.

[4]  P. Musiani,et al.  Androgen Deprivation Boosts Prostatic Infiltration of Cytotoxic and Regulatory T Lymphocytes and Has No Effect on Disease-Free Survival in Prostate Cancer Patients , 2010, Clinical Cancer Research.

[5]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. , 2010, Cancer research.

[6]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[7]  T. Malek,et al.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity. , 2010, Immunity.

[8]  M. Sanda,et al.  Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic mice , 2010, The Prostate.

[9]  S. Maiella,et al.  In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2–treated HIV patients , 2010, Proceedings of the National Academy of Sciences.

[10]  M. L. Moore,et al.  In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. , 2010, Cancer research.

[11]  F. Alvarez,et al.  Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis , 2010, Hepatology.

[12]  I. Svane,et al.  Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2 , 2010, Journal of immunotherapy.

[13]  C. Rinaldo,et al.  Regulatory T Cell Suppression of Gag-Specific CD8+ T Cell Polyfunctional Response After Therapeutic Vaccination of HIV-1-Infected Patients on ART , 2010, PloS one.

[14]  N. Chaput,et al.  Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. , 2009, International journal of oncology.

[15]  Andrew N. Gray,et al.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization , 2009, The Prostate.

[16]  Lisa M. Ebert,et al.  Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma , 2009, Clinical Cancer Research.

[17]  Elisabeth Jones,et al.  Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression , 2009 .

[18]  Elisabeth Jones,et al.  Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. , 2009, Expert opinion on therapeutic targets.

[19]  S. Quezada,et al.  Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma , 2008, The Journal of experimental medicine.

[20]  L. Lefrançois,et al.  Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. , 2008, Immunity.

[21]  A. Scheffold,et al.  IL‐2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells , 2008, European journal of immunology.

[22]  P. Lowenstein,et al.  Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials , 2008, PloS one.

[23]  T. Ley,et al.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.

[24]  D. Kosec,et al.  Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level. , 2007, The Journal of endocrinology.

[25]  S. Zheng,et al.  IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.

[26]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[27]  P. Nelson,et al.  Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. , 2006, American journal of physiology. Endocrinology and metabolism.

[28]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[29]  A. Scheffold,et al.  Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL‐)two to tango , 2005, European journal of immunology.

[30]  A. Rudensky,et al.  TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells , 2005, The Journal of experimental medicine.

[31]  Shimon Sakaguchi,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[32]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[33]  M. Veldhoen,et al.  CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. , 2005, International immunology.

[34]  M. Neurath,et al.  Cutting Edge: TGF-β Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells1 , 2004, The Journal of Immunology.

[35]  B. Leibovich,et al.  Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation1 , 2004, The Journal of Immunology.

[36]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[37]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[38]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[39]  L. Klein,et al.  In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Isaacs,et al.  A history of prostate cancer treatment , 2002, Nature Reviews Cancer.

[41]  M. T. Moser,et al.  T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[43]  J. Shabanowitz,et al.  The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.

[44]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[45]  N. Olsen,et al.  Castration alters peripheral immune function in normal male mice. , 1995, Immunology.

[46]  M. Kattan,et al.  Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[47]  M. Kattan,et al.  Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[48]  M. Steiner,et al.  Expression of transforming growth factor-beta 1 in prostate cancer. , 1994, Endocrinology.